7,179 Shares in DaVita Inc. (NYSE:DVA) Bought by Versor Investments LP

Versor Investments LP bought a new position in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 7,179 shares of the company’s stock, valued at approximately $1,177,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Harvard Management Co. Inc. acquired a new stake in DaVita during the second quarter worth approximately $55,115,000. Lazard Asset Management LLC grew its stake in shares of DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock valued at $35,460,000 after buying an additional 153,008 shares during the period. Jupiter Asset Management Ltd. increased its position in DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock valued at $25,840,000 after buying an additional 111,311 shares in the last quarter. Point72 Asset Management L.P. bought a new position in DaVita in the second quarter worth approximately $9,615,000. Finally, International Assets Investment Management LLC bought a new position in shares of DaVita in the 3rd quarter worth $10,346,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Buying and Selling at DaVita

In other news, COO Michael David Staffieri sold 9,539 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at approximately $36,299,008.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares in the company, valued at approximately $36,299,008.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 50,000 shares of DaVita stock in a transaction on Monday, September 16th. The shares were sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 165,625 shares of company stock worth $26,238,297 over the last ninety days. Insiders own 2.00% of the company’s stock.

DaVita Stock Up 3.2 %

Shares of NYSE DVA opened at $154.48 on Tuesday. The business has a 50-day simple moving average of $157.22 and a two-hundred day simple moving average of $147.05. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The company has a market cap of $12.67 billion, a P/E ratio of 16.66, a P/E/G ratio of 0.84 and a beta of 0.89. DaVita Inc. has a 52 week low of $84.64 and a 52 week high of $168.50.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. During the same quarter last year, the business posted $2.85 EPS. The business’s revenue was up 4.6% compared to the same quarter last year. Research analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. TD Cowen boosted their target price on DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, July 24th. UBS Group lifted their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Truist Financial upped their price objective on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. Finally, Barclays increased their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.